Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Cisplatin + RP3 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Cisplatin | Platinol | CDDP | Chemotherapy - Platinum 7 | Platinol (cisplatin) is a platinum based chemotherapeutic, which is FDA approved for bladder, ovarian, and testicular cancers (NCI Drug Dictionary). |
RP3 | RP 3|RP-3 | RP3 is an oncolytic virus engineered to express a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) targeting antibody, CD40 ligand, and tumor necrosis factor ligand superfamily member 9 (TNFSF9), which may result in activation of anti-tumor immune response and tumor cell killing (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05743270 | Phase II | Cisplatin Nivolumab Cisplatin + RP3 Carboplatin + Paclitaxel + RP3 | Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN | Withdrawn | USA | POL | GRC | GBR | FRA | ESP | DEU | CZE | 0 |